Similar articles

• Summaries for patients. Cost-effectiveness of alendronate in postmenopausal women with low bone mass without osteoporosis or previous fracture.

  [No authors listed] [No authors listed] Ann Intern Med. 2005 May 3;142(9):I36. doi: 10.7326/0003-4819-142-9-200505030-00002. Ann Intern Med. 2005. PMID: 15867399 No abstract available.
• Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women.

  Schousboe JT, Nyman JA, Kane RL, Ensrud KE. Schousboe JT, et al. Ann Intern Med. 2005 May 3;142(9):734-41. doi: 10.7326/0003-4819-142-9-200505030-00008. Ann Intern Med. 2005. PMID: 15867405
• Cost-effectiveness of alendronate for the treatment of osteopenic postmenopausal women in Japan.

  Moriwaki K, Komaba H, Noto S, Yanagisawa S, Takiguchi T, Inoue H, Toujo T, Fukagawa M, Takahashi HE. Moriwaki K, et al. J Bone Miner Res. 2013 Feb;28(2):395-403. doi: 10.1002/jbmr.1755. J Bone Miner Res. 2013. PMID: 22991163
• Clinical practice. Osteopenia.

  Khosla S, Melton LJ 3rd. Khosla S, et al. N Engl J Med. 2007 May 31;356(22):2293-300. doi: 10.1056/NEJMcp070341. N Engl J Med. 2007. PMID: 17538088 Review. No abstract available.
• [Osteoporosis: prevention of bone loss and fractures].

  Pfeifer M, Begerow B, Pollähne W, Minne HW. Pfeifer M, et al. MMW Fortschr Med. 2002 Nov 28;144(48):I-VIII; quiz IX-X. MMW Fortschr Med. 2002. PMID: 12532553 Review. German. No abstract available.